Rtw Investments buys $20.8 Million stake in Achillion Pharmaceuticals (ACHN)

Achillion Pharmaceuticals (ACHN) : Rtw Investments scooped up 606,937 additional shares in Achillion Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 2,558,859 shares of Achillion Pharmaceuticals which is valued at $20.8 Million.Achillion Pharmaceuticals makes up approximately 8.36% of Rtw Investments’s portfolio.

Other Hedge Funds, Including , Teacher Retirement System Of Texas boosted its stake in ACHN in the latest quarter, The investment management firm added 3,452 additional shares and now holds a total of 13,424 shares of Achillion Pharmaceuticals which is valued at $109,271.Blackrock Advisors boosted its stake in ACHN in the latest quarter, The investment management firm added 10,320 additional shares and now holds a total of 104,397 shares of Achillion Pharmaceuticals which is valued at $849,792.Swiss National Bank boosted its stake in ACHN in the latest quarter, The investment management firm added 33,100 additional shares and now holds a total of 185,500 shares of Achillion Pharmaceuticals which is valued at $1.5 Million. Globeflex Capital L P added ACHN to its portfolio by purchasing 87,200 company shares during the most recent quarter which is valued at $690,624. Achillion Pharmaceuticals makes up approx 0.19% of Globeflex Capital L P’s portfolio.Ifp Advisors Inc boosted its stake in ACHN in the latest quarter, The investment management firm added 200 additional shares and now holds a total of 530 shares of Achillion Pharmaceuticals which is valued at $4,198.

Achillion Pharmaceuticals opened for trading at $8.19 and hit $8.36 on the upside on Monday, eventually ending the session at $8.24, with a gain of 1.23% or 0.1 points. The heightened volatility saw the trading volume jump to 13,48,619 shares. Company has a market cap of $1,126 M.

On the company’s financial health, Achillion Pharmaceuticals reported $-0.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on May 3, 2016. Analyst had a consensus of $-0.14.During the same quarter in the previous year, the company posted $-0.17 EPS.

Many Wall Street Analysts have commented on Achillion Pharmaceuticals. Robert W. Baird Upgraded Achillion Pharmaceuticals on Feb 26, 2016 to ” Outperform”, Price Target of the shares are set at $10.Shares were Reiterated by Maxim Group on Feb 25, 2016 to “Buy” and Lowered the Price Target to $ 8 from a previous price target of $11 .

Achillion Pharmaceuticals Inc. is a biopharmaceutical company. The Company’s primary business is to discover develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus or HCV infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens including ACH-3102 a NS5A inhibitor which is under Phase II clinical development ACH-3422 a NS5B nucleotide polymerase inhibitor which is under Phase I clinical development and Sovaprevir a NS3 protease inhibitor which is under Phase II clinical development.

Leave a Reply

Achillion Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Achillion Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.